Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: March 17, 2026, 5:09 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 539680 | NSE: GANGAPHARM

Ganga Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹11.44Fairly Valued by 4.67%vs CMP ₹12.00

P/E (88.6) × ROE (1.1%) × BV (₹14.00) × DY (2.00%)

₹8.57Overvalued by 28.58%vs CMP ₹12.00
MoS: -40% (Negative)Confidence: 45/100 (Moderate)Models: 1 Under, 1 Fair, 4 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹12.4034%Fair (+3.3%)
Graham NumberEarnings₹6.8725%Over (-42.8%)
Net Asset ValueAssets₹14.0111%Under (+16.8%)
Earnings YieldEarnings₹1.5011%Over (-87.5%)
ROCE CapitalReturns₹5.3011%Over (-55.8%)
Revenue MultipleRevenue₹4.208%Over (-65%)
Consensus (6 models)₹8.57100%Overvalued
Key Drivers: ROE 1.1% is below cost of equity. | Wide model spread (₹2–₹14) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 8.4%

*Investments are subject to market risks

Investment Snapshot

47
Ganga Pharmaceuticals Ltd scores 47/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health59/100 · Moderate
ROCE 3.2% WeakROE 1.1% WeakD/E 0.29 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money35/100 · Weak
Promoter decreased by 5.11% Caution
Earnings Quality40/100 · Moderate
OPM stable around -1% SteadyWorking capital: 731 days Capital intensive
Quarterly Momentum70/100 · Strong
Revenue (4Q): +6% YoY GrowingProfit (4Q): +44% YoY StrongOPM: -1.5% (down 5.3% YoY) Margin pressure
Industry Rank15/100 · Weak
P/E 88.6 vs industry 53.8 Premium to peersROCE 3.2% vs industry 16.4% Below peersROE 1.1% vs industry 15.2% Below peers3Y sales CAGR: 2% Slow

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: March 17, 2026, 5:09 am

Market Cap 7.09 Cr.
Current Price 12.0
Intrinsic Value₹8.57
High / Low 14.8/9.35
Stock P/E88.6
Book Value 14.0
Dividend Yield0.00 %
ROCE3.18 %
ROE1.13 %
Face Value 10.0
PEG Ratio10.49

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Ganga Pharmaceuticals Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Ganga Pharmaceuticals Ltd 7.09 Cr. 12.0 14.8/9.3588.6 14.00.00 %3.18 %1.13 % 10.0
Neuland Laboratories Ltd 16,182 Cr. 12,613 19,748/10,06090.3 1,2630.10 %18.7 %14.8 % 10.0
Astrazeneca Pharma India Ltd 19,630 Cr. 7,852 10,691/6,50294.4 3200.41 %33.4 %23.6 % 2.00
Bacil Pharma Ltd 71.9 Cr. 50.1 51.9/26.797.2 18.40.00 %0.97 %0.98 % 10.0
Hikal Ltd 1,972 Cr. 160 457/14678.9 96.90.88 %9.85 %7.38 % 2.00
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Ganga Pharmaceuticals Ltd

Quarterly Result

MetricSep 2019Mar 2020Sep 2020Mar 2021Sep 2021Mar 2022Sep 2022Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025
Sales 1.381.701.141.231.251.241.351.231.321.421.311.331.37
Expenses 1.101.601.071.281.231.231.281.301.271.411.421.331.39
Operating Profit 0.280.100.07-0.050.020.010.07-0.070.050.01-0.110.00-0.02
OPM % 20.29%5.88%6.14%-4.07%1.60%0.81%5.19%-5.69%3.79%0.70%-8.40%0.00%-1.46%
Other Income 0.080.090.070.190.110.150.120.180.090.150.290.140.15
Interest 0.120.120.090.100.100.090.120.070.090.090.090.090.07
Depreciation 0.030.030.030.030.030.030.030.030.030.020.020.020.03
Profit before tax 0.210.040.020.010.000.040.040.010.020.050.070.030.03
Tax % 23.81%25.00%50.00%100.00%25.00%25.00%0.00%50.00%20.00%57.14%-66.67%33.33%
Net Profit 0.160.030.020.000.000.030.030.010.020.030.020.060.02
EPS in Rs 0.390.070.050.000.000.070.070.020.050.060.040.120.03

Last Updated: December 26, 2025, 9:06 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: December 15, 2025, 3:41 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 2.662.442.452.632.733.182.992.272.322.472.582.482.70
Expenses 2.432.192.152.322.412.762.612.242.282.472.532.602.72
Operating Profit 0.230.250.300.310.320.420.380.030.040.000.05-0.12-0.02
OPM % 8.65%10.25%12.24%11.79%11.72%13.21%12.71%1.32%1.72%0.00%1.94%-4.84%-0.74%
Other Income 0.150.170.140.160.150.140.170.250.260.300.240.440.29
Interest 0.300.330.330.320.280.250.240.190.190.190.180.180.16
Depreciation 0.030.040.040.040.060.050.050.050.050.060.050.050.05
Profit before tax 0.050.050.070.110.130.260.260.040.060.050.060.090.06
Tax % 40.00%40.00%28.57%27.27%23.08%30.77%23.08%50.00%16.67%40.00%33.33%11.11%
Net Profit 0.030.030.050.070.090.190.190.020.040.040.050.080.08
EPS in Rs 0.130.130.120.170.220.470.470.050.100.100.100.170.15
Dividend Payout % 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)0.00%66.67%40.00%28.57%111.11%0.00%-89.47%100.00%0.00%25.00%60.00%
Change in YoY Net Profit Growth (%)0.00%66.67%-26.67%-11.43%82.54%-111.11%-89.47%189.47%-100.00%25.00%35.00%

Ganga Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:0%
5 Years:-4%
3 Years:2%
TTM:-4%
Compounded Profit Growth
10 Years:10%
5 Years:-16%
3 Years:26%
TTM:60%
Stock Price CAGR
10 Years:%
5 Years:6%
3 Years:13%
1 Year:-25%
Return on Equity
10 Years:2%
5 Years:1%
3 Years:1%
Last Year:1%

Last Updated: September 5, 2025, 3:31 pm

Balance Sheet

Last Updated: March 3, 2026, 3:01 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 2.332.334.064.064.064.064.064.064.064.064.844.845.91
Reserves 0.280.310.740.810.911.091.291.311.351.392.212.292.37
Borrowings 2.072.142.192.142.051.871.471.731.931.831.361.421.56
Other Liabilities 0.460.610.350.601.220.740.750.560.660.710.240.420.32
Total Liabilities 5.145.397.347.618.247.767.577.668.007.998.658.9710.16
Fixed Assets 0.650.650.620.620.820.800.760.720.680.640.610.660.66
CWIP 0.000.000.000.000.000.000.000.000.000.000.000.000.00
Investments 0.050.050.500.000.000.090.090.090.090.090.090.000.00
Other Assets 4.444.696.226.997.426.876.726.857.237.267.958.319.50
Total Assets 5.145.397.347.618.247.767.577.668.007.998.658.9710.16

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + -0.210.27-1.050.050.240.11-0.31-0.18-0.21-0.04-1.26-0.58
Cash from Investing Activity + -0.23-0.18-0.830.62-0.140.280.370.280.190.490.131.18
Cash from Financing Activity + 0.43-0.061.90-0.33-0.36-0.45-0.29-0.100.03-0.441.14-0.33
Net Cash Flow -0.010.030.020.33-0.26-0.05-0.220.000.010.010.000.27
Free Cash Flow -0.230.23-1.060.01-0.020.08-0.32-0.20-0.22-0.05-1.28-0.68
CFO/OP -91%104%-347%29%88%40%-66%-567%-500%-2,480%475%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-1.84-1.89-1.89-1.83-1.73-1.45-1.09-1.70-1.89-1.83-1.31-1.54

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 94.68109.20140.04173.48211.25141.18130.62131.85140.02131.52130.16133.93
Inventory Days 312.46288.16374.86385.66358.71341.26296.56332.62330.51347.34362.08353.03
Days Payable 105.08118.0198.65182.50330.39163.21159.69129.52152.32170.7329.2083.77
Cash Conversion Cycle 302.07279.35416.26376.64239.56319.23267.49334.96318.21308.13463.04403.19
Working Capital Days 222.29142.11467.80428.84417.14387.96449.23477.56503.45477.31639.46731.47
ROCE %7.87%8.03%6.80%6.14%5.84%7.26%7.23%3.30%3.46%3.28%3.06%3.18%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthJun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025
Promoters 66.71%66.71%66.71%66.71%66.71%66.71%66.71%66.71%56.02%56.02%56.02%50.91%
Public 33.29%33.29%33.29%33.29%33.29%33.29%33.29%33.28%43.98%43.98%43.98%49.09%
No. of Shareholders 354354354356356355356359363365368366

Shareholding Pattern Chart

No. of Shareholders

Ganga Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 0.160.110.100.090.05
Diluted EPS (Rs.) 0.120.070.100.090.05
Cash EPS (Rs.) 0.250.190.230.220.18
Book Value[Excl.RevalReserv]/Share (Rs.) 14.7414.5813.4213.3213.23
Book Value[Incl.RevalReserv]/Share (Rs.) 14.7414.5813.4213.3213.23
Revenue From Operations / Share (Rs.) 5.455.666.376.135.85
PBDIT / Share (Rs.) 0.660.610.740.740.70
PBIT / Share (Rs.) 0.560.510.600.600.57
PBT / Share (Rs.) 0.190.130.130.120.09
Net Profit / Share (Rs.) 0.160.090.090.090.05
PBDIT Margin (%) 12.1210.8611.7112.0812.01
PBIT Margin (%) 10.359.069.539.889.75
PBT Margin (%) 3.592.312.052.051.57
Net Profit Margin (%) 2.991.701.511.520.85
Return on Networth / Equity (%) 1.100.660.720.700.37
Return on Capital Employeed (%) 3.703.324.053.893.82
Return On Assets (%) 0.880.530.490.470.26
Long Term Debt / Equity (X) 0.030.050.110.160.12
Total Debt / Equity (X) 0.190.190.330.330.29
Asset Turnover Ratio (%) 0.290.320.320.310.31
Current Ratio (X) 4.284.812.722.912.86
Quick Ratio (X) 3.553.772.092.232.15
Inventory Turnover Ratio (X) 2.181.091.151.131.31
Interest Coverage Ratio (X) 1.791.611.561.541.47
Interest Coverage Ratio (Post Tax) (X) 1.441.251.201.191.10
Enterprise Value (Cr.) 6.0413.137.465.954.59
EV / Net Operating Revenue (X) 2.294.802.882.391.93
EV / EBITDA (X) 18.8944.2024.6119.8016.09
MarketCap / Net Operating Revenue (X) 1.874.322.191.671.28
Price / BV (X) 0.681.671.040.760.56
Price / Net Operating Revenue (X) 1.874.322.191.671.28
EarningsYield 0.010.000.010.010.01

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Ganga Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 11/09/1989 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L99999MH1989PLC053392 and registration number is 053392. Currently company belongs to the Industry of Pharmaceuticals. Company's Total Operating Revenue is Rs. 2.64 Cr. and Equity Capital is Rs. 4.84 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsGangatat, Dhanvantary Marg, Palghar Maharashtra 401305Contact not found
Management
NamePosition Held
Mr. Sanjay Vyankatesh KulkarniChairman & Non-Exe.Director
Mr. Bharat Brijmohan SharmaManaging Director & CEO
Mrs. Srijna Bharat SharmaWhole Time Director
Mr. Munna Baijnath ChaurasiaIndependent Director
Mr. Aman Mukesh ChaudhariIndependent Director

FAQ

What is the intrinsic value of Ganga Pharmaceuticals Ltd and is it undervalued?

As of 09 April 2026, Ganga Pharmaceuticals Ltd's intrinsic value is ₹8.57, which is 28.58% lower than the current market price of ₹12.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (1.13 %), book value (₹14.0), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Ganga Pharmaceuticals Ltd?

Ganga Pharmaceuticals Ltd is trading at ₹12.00 as of 09 April 2026, with a FY2026-2027 high of ₹14.8 and low of ₹9.35. The stock is currently in the middle of its 52-week range. Market cap stands at ₹7.09 Cr..

How does Ganga Pharmaceuticals Ltd's P/E ratio compare to its industry?

Ganga Pharmaceuticals Ltd has a P/E ratio of 88.6, which is above the industry average of 53.84. The premium over industry average may reflect growth expectations or speculative interest.

Is Ganga Pharmaceuticals Ltd financially healthy?

Key indicators for Ganga Pharmaceuticals Ltd: ROCE of 3.18 % is on the lower side compared to the industry average of 16.35%; ROE of 1.13 % is below ideal levels (industry average: 15.16%). Dividend yield is 0.00 %.

Is Ganga Pharmaceuticals Ltd profitable and how is the profit trend?

Ganga Pharmaceuticals Ltd reported a net profit of ₹0 Cr in Mar 2025 on revenue of ₹2 Cr. Compared to ₹0 Cr in Mar 2022, the net profit shows an improving trend.

Does Ganga Pharmaceuticals Ltd pay dividends?

Ganga Pharmaceuticals Ltd has a dividend yield of 0.00 % at the current price of ₹12.00. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Ganga Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports